Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 17/20 | 0.62 |
| ▸ | PDE3A | Q14432 | 17/20 | 0.62 |
| ▸ | GALR3 | O60755 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | THRB | P10828 | 1/20 | 0.60 |
| ▸ | PDE4A | P27815 | 3/20 | 0.59 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.59 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.59 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.59 |
| ▸ | TNNC1 | P63316 | 1/20 | 0.55 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL934905 | 1.00 | PDE3B (0.62) | PDE3BPDE3AGALR3MAPTTHRB | |
| SCHEMBL5681256 | 1.00 | PDE3B (0.62) | PDE3BPDE3AGALR3MAPTTHRB | |
| Alcohol SCHEMBL22130251 | 0.93 | PDE3B (0.59) | PDE3BPDE3AGALR3MAPTTHRB | |
| SCHEMBL10353457 | 0.92 | PDE3B (0.71) | PDE3BPDE3AGALR3MAPTTHRB | |
| SCHEMBL8342501 | 0.85 | PDE3B (0.64) | PDE3BPDE3AGALR3MAPTTHRB | |
| SCHEMBL10016799 | 0.85 | PDE3B (0.64) | PDE3BPDE3AGALR3MAPTTHRB | |
| SCHEMBL9687674 | 0.85 | PDE3B (0.64) | PDE3BPDE3AGALR3MAPTTHRB | |
| SCHEMBL22317993 | 0.85 | PDE3B (0.64) | PDE3BPDE3AGALR3MAPTTHRB | |
| SCHEMBL11633346 | 0.85 | PDE3B (0.64) | PDE3BPDE3AGALR3MAPTTHRB | |
| SCHEMBL992766 | 0.84 | GALR3 (0.72) | PDE3BPDE3AGALR3MAPTTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018086703-A1 | DIHYDROPYRIDAZINONES SUBSTITUTED WITH PHENYLUREAS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-05-17 | — | — | WO | disclosed |
| US-20120165524-A1 | Process for Preparing Levosimendan and Intermediates for Use in the Process | CIPLA LIMITED (IN) | 2012-06-28 | — | — | US | disclosed |
| US-20120165524-A1 | Process for Preparing Levosimendan and Intermediates for Use in the Process | CIPLA LIMITED (IN) | 2012-06-28 | — | — | US | disclosed |
| WO-2011007123-A1 | PROCESS FOR PREPARING LEVOSIMENDAN AND INTERMEDIATES FOR USE IN THE PROCESS | CIPLA LIMITED (IN) | 2011-01-20 | — | — | WO | disclosed |
| US-5246928-A | Cardiovascular disorders | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1993-09-21 | — | — | US | disclosed |
| US-5066653-A | Cardiovascular disorders; bronchodilators; phosphodiesterase inhibitors | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1991-11-19 | — | — | US | disclosed |
| CN-1009092-B | The preparation method of Pyridione derivatives | SMITH KLINE FRENCH LAB (GB) | 1990-08-08 | — | — | CN | disclosed |
| US-4906628-A | N-phenylpyridone type III phosphodiesterases | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1990-03-06 | — | — | US | disclosed |
| CN-86106546-A | The preparation method of Pyridione derivatives | — | 1987-05-20 | — | — | CN | disclosed |
| EP-0220044-A2 | 4(4-oxo-1,4-dihydropyridin-1-yl)phenyl derivatives | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1987-04-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165524-A1 | Process for Preparing Levosimendan and Intermediates for Use in the Process | CYP3A5, HTR5A, CYP2D6 | PDE3B 375/4885PDE3A 220/4885GALR3 3357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.